The purpose of this review is to provide readers with guidance concerning treatment of patients with advanced, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in the context of clinical trial data. We discuss issues surrounding the treatment of patients with SCCHN, with an emphasis on recommendations based on results from phase II and III clinical trials published since 1980. Many options exist for the treatment of patients with SCCHN. The most important decisions involve determining which patients are in need of treatment and which are most likely to benefit from treatment. Although many chemotherapy treatments have been shown to induce responses, survival improvement remains an unfulfilled goal. Definitive data do not exist on the effects of chemotherapy on quality of life or progression-free survival as measures of clinical benefit in this setting. Performance status, history of prior treatment, extent of tumor, and need for palliation are the most important factors in the decision to treat a patient with chemotherapy for incurable SCCHN. Single-agent treatment with conventional doses of methotrexate remains a standard for most patients with advanced, recurrent or metastatic SCCHN. Cisplatin plus fluorouracil, cisplatin plus a taxane, and single-agent taxane are the most widely studied alternatives. There is a need for further trials with end points other than overall survival or tumor response in this patient population. Guidelines for patient selection and treatment options are provided.
INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) region is one of the more chemotherapysensitive human neoplasms. Response rates approaching 70% have been reported with singleagent treatment, and recent reports demonstrate that overall response rates and complete response rates approaching 90% and 60%, respectively are achievable. [1] [2] [3] Despite the advances made in the treatment of patients with SCCHN confined to the primary and neck region, many of these patients still relapse and are not candidates for salvage surgery or radiation treatment. Most of these patients die as a result of complications of their cancer. [4] [5] [6] 7 Additionally, patients present with metastatic disease and are therefore not eligible for multimodality potentially curative treatment.
Because patients with recurrent or metastatic disease are generally incurable, the goals of treatment are more limited, and include prolongation of overall survival (OS) or progression-free survival (PFS), palliation of existing symptoms, and prevention of new cancer-related symptoms. While improvement in survival has been the holy grail of treatment in this setting, no chemotherapy treatment has been convincingly demonstrated to prolong survival. Additionally, a correlation between tumor shrinkage and benefit such as symptom reduction or improvement in quality of life has not been rigorously evaluated. These factors underscore the importance of clinical trials for this patient group.
THE INITIAL EVALUATION: WHICH PATIENTS ARE MOST LIKELY TO BENEFIT FROM TREATMENT?
Multivariable analyses from palliative chemotherapy clinical trials have shown that time to progression and survival are greatly influenced by factors other than the specific chemotherapy administered. Poor performance status, prior treatment (chemotherapy, surgery, or radiation), and advanced stage of disease are all associated with a marked reduction in the response rate to chemotherapy. These three factors plus lack of response to chemotherapy are strongly correlated with shorter survival duration, suggesting that for single-arm clinical trials, patient selection has been at least as important as the type of therapy administered. [8] [9] [10] [11] Therefore, response to chemotherapy may be a prognostic marker for patients destined to do well. The fundamental question concerning the survival benefit of any chemotherapy treatment remains unanswered because an adequately powered randomized, controlled clinical trial comparing chemotherapy treatment with supportive care has not been performed.
Additional predictors of poor outcome or shortened survival that should be considered when making treatment decisions include the presence of hypercalcemia and comorbidities such as poor cognitive function; ongoing heavy tobacco, alcohol, or other carcinogen use; and the absence of a strong social support system. [12] [13] [14] For example, even in the era of bisphosphonates, the prognosis for SCCHN patients with hypercalcemia is dismal, with median survival of 35 days.
15 Table 1 summarizes the main adverse prognostic features in patients with SCCHN. One can anticipate that patients without these adverse outcome predictors would be more likely to benefit from palliative chemotherapy.
CHEMOTHERAPY TREATMENT OF SCCHN:
A HISTORICAL PERSPECTIVE Before US Food and Drug Administration approval of cisplatin (CDDP) in 1978, the role of the medical oncologist was strictly palliation of patients with advanced incurable disease. Methotrexate (MTX) and bleomycin were the most widely used cytotoxics.
Response rates to MTX as high as 77% have been reported in patients with no prior treatment. 16 The most widely studied and used dosing is weekly intravenous administration of 40 to 60 mg/m 2 . Higher doses of MTX are associated with both increased response rates and toxicity, but do not improve survival. 17, 18 Response rates to bleomycin are in the 15% to 20% range.
As early as 1977, CDDP was found to induce rapid responses in 30% of patients who had been heavily pretreated with surgery, radiation, and chemotherapy. Higher response rates were seen in patients without prior treatment. 19, 20 Other cytotoxics shown to have response rates exceeding 15% included carboplatin (CARBO), cyclophosphamide, doxorubicin, hydroxyurea, vinblastine, and fluorouracil (FU). Table 2 summarizes the response data for agents with clinically relevant single-agent activity against SCCHN.
Through the early 1980s, MTX, CDDP, FU, and bleomycin were regarded as the most useful agents in SCCHN on the basis of objective response rates. [8] [9] [10] Only one small study was designed to demonstrate clinical benefit over supportive care using randomized controlled trial (RCT) methodology. In this trial, 31 patients treated with single-agent  CDDP demonstrated prolonged survival compared with 26 patients  treated with supportive measures. 21 This same trial demonstrated that patients who respond do so quickly. Of the 16 responders, 75% responded after the first cycle and the remaining 25% after the second cycle.
RANDOMIZED TRIALS OF NON-TAXANE REGIMENS AND META-ANALYSIS
In the 1980s, a number of RCTs compared various combinations of platinums and other chemotherapeutics (Table 3 ). The outcome of these trials analyzed individually can be summarized as follows: CDDP as a single agent is not superior to MTX in terms of response or median survival. 22 The combination of CARBO and MTX is not superior to MTX alone. 23 Multiagent chemotherapy in general is associated with higher response rates than single-agent treatment. CDDP-and multiagent-containing regimens are associated with more high-grade toxicity than single-agent treatment. Platinumcontaining combination regimens have the highest response rates, occasionally approaching 50% in the RCT setting. [24] [25] [26] [27] None of these trials have demonstrated a survival superiority of one regimen versus another.
Meta-analytic evaluation and interpretation of a subset of trials from this era demonstrated a statistically significant response superiority to combination versus single-agent treatment, but paradoxically the median survival trends slightly favored single agents over combinations 28 Only the response and survival results for CDDP ϩ FU versus single agents and other combinations were not discordant. Probably the most salient piece of survival information from this meta-analysis was that the difference in median survival in all comparisons was quite modest: 4 to 25 days. There was a substantial increase in nausea and vomiting associated with CDDP ϩ FU regimens. However, these and many of the subsequently discussed controlled trials were conducted in the era before the widespread use of effective 5-HT3 receptor antagonists for nausea.
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CDDP AND FU
The combination of CDDP ϩ FU emerged as a favored treatment regimen in the 1980s and 1990s. This was based initially on two phase II trials published in the mid-1980s testing induction chemotherapy, in which response rates of 67% and 70% with complete response rates of 19% and 27% were seen. 31, 32 Response rates were notably lower for the subsets of patients who had prior surgery and radiation and those who had metastatic disease.
Results from two RCTs designed to compare platinum ϩ FU with single-agent chemotherapy in patients with advanced SCCHN were published in 1992 (Table 3 ). The first trial compared CDDP ϩ FU and CARBO ϩ FU with MTX. The second trial compared CDDP ϩ FU with CDDP and FU as single agents. 33, 34 The overall response rates to CDDP ϩ FU and CARBO ϩ FU were 32% and 21%, respectively. The response rates to the single-agent treatments were 17% to CDDP, 13% to FU and 10% to MTX, all significantly lower than CDDP ϩ FU. Median survival, however, was approximately 6 months for all treatment arms. Grade 3 to 4 toxicity rates with CDDP ϩ FU were nearly double the rates of the other treatment arms. In 1994, one of the largest studies (382 patients) published to date in this patient population compared CDDP ϩ FU and CABO (CDDP ϩ MTX ϩ bleomycin ϩ vincristine) with CDDP alone. Both the CDDP ϩ FU and CABO arms demonstrated higher response rates and time to progression (TTP) than CDDP, but median survival was 7.3 months in all arms, and high-grade toxicity occurred more often in the combination arms, with CDDP ϩ FU being the highest.
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In summary, when using response rates as the clinical trial end point for recurrent disease, CDDP-based combinations appeared to be superior to single agents, but at a cost of greater toxicity and without demonstrating improved survival or other indicators of clinical benefit.
THE TAXANES
During the 1990s, a large number of new agents were tested in patients with advanced SCCHN (Table 2 ). Both docetaxel and paclitaxel stood out as having high single-agent response rates (21% to 42%), [36] [37] [38] [39] [40] but were accompanied by high rates of severe toxicity. Because many of these trials were limited to patients with excellent performance status, it is possible that the high response rates were at least partially caused by patient selection. Paclitaxel 250 mg/m 2 on the 24-hour infusion schedule every 3 weeks was associated with hospitalizations for febrile neutropenia in 15% of patients in one trial and four early deaths from sepsis in another. 39, 40 Docetaxel administered at 100 mg/m 2 as a 1-hour infusion resulted in a 53% rate of febrile neutropenia. 37 Attempts to increase the therapeutic index of paclitaxel in patients with advanced SCCHN by changing the schedule of infusion have been variably successful.
41 Subsequent routine use of taxanes in SCCHN patients has been at lower doses with shorter infusion schedules (docetaxel, 1 hour; paclitaxel, 3 hours) to increase tolerability. There is a clinical impression that bone marrow suppression is reduced, whereas significant anticancer activity persists; however, there are no RCTs to confirm this impression.
Although some investigators have emphasized the potential therapeutic differences between docetaxel and paclitaxel, there have been no direct comparisons in SCCHN patients to confirm this hypothesis. 42, 43 However, a large experience from other tumor types is instructive. [44] [45] [46] [47] In cancers responsive to taxanes, docetaxel and paclitaxel are reasonably active on both the weekly and every-21-days schedules. Docetaxel administered every 3 weeks is probably more active and associated with more adverse events than when administered on a weekly schedule, whereas weekly paclitaxel may be both Abbreviations: SCCHN, squamous cell carcinoma of the head and neck; CR, complete response; SD, stable disease; NPC, nasopharyngeal carcinoma.
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better tolerated and more efficacious than when administered every 21 days. [48] [49] [50] 51 Docetaxel seems to be more bone marrow and GI toxic than paclitaxel, whereas paclitaxel is more neuropathic than docetaxel, but neither of these adverse event profiles have not been associated with a worse quality of life. 49, 52, 53 There are limited data concerning single-agent taxane treatment versus other single agents. One RCT of MTX versus docetaxel demonstrated higher response rates to docetaxel but no median survival difference.
54 Two trials comparing MTX with paclitaxel closed prematurely without publication of data because of lack of adequate enrollment and lack of sufficient activity in all arms, respectively. 55, 56 Because of the high single-agent activity of the taxanes and the potentially nonoverlapping toxicity of taxanes and platinums, combinations of paclitaxel ϩ CDDP, paclitaxel ϩ CARBO and docetaxel ϩ CDDP, have been tested extensively in patients with good performance status (0 to 1; Table 4) . 47, [57] [58] [59] [60] [61] Response rates of 27% to 53% and median survival of 5 to 12 months were reported. These response rates and survival durations were promising compared with the historical CDDP ϩ FU experience because many of these trials included patients with prior surgery and radiation treatment. Combinations of taxanes plus FU have been less promising, with response rates of 25% or less.
62,63 Trials of taxanes plus gemcitabine are ongoing. Two RCTs have defined the utility of paclitaxel ϩ CDDP in patients with recurrent or metastatic SCCHN. In one trial, 218 patients, mostly with recurrent disease, were randomly assigned between CDDP ϩ FU and CDDP ϩ paclitaxel. Response rates and median survival durations in the two arms were virtually identical, 27% and 8 months respectively. The 1-year survival rate was 41% for the CDDP ϩ FU control arm and 32% for the CDDP ϩ paclitaxel arm, but these differences were not statistically significant. The number of high-grade toxicities reported in the CDDP ϩ FU arm exceeded those in the CDDP ϩ paclitaxel arm by a factor of 1.6. 64 The second RCT of the CDDP ϩ paclitaxel combination compared two doses of paclitaxel administered as a 24-hour infusion, 200 mg/m 2 and 135 mg/m 2 .
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Response rates and median survival in the two arms were statistically indistinguishable, approximately 35% and 7 months, respectively. Hematologic toxicity was thought to be excessive in both arms. Aggressive triple-agent protocols such as paclitaxel, ifosfamide, and CDDP or CARBO (TIP and TIC), and docetaxel, CDDP, and FU (TPF) have response rates approaching 60% and complete response ‫ء‬ Wherever toxicity was quantified by grade, relative number or percentage of grade 3 to 5 toxicities are reported. This is a sum of the worst event per patient for each toxicity type based on either absolute values or percentages reported in the publication. †Majority of patients on this trial had prior therapy (excluding chemotherapy).
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www.jco.org(CR) rates in the 15% range in patients with prior chemotherapy, median response durations of 4 to 7 months, and median survival of 9 to 11 months. Although these results suggest potential improvement over two-drug regimens, the best reported 1-year survival rate was 40% which was similar to recent trials of CDDP/FU but with added toxicity. 1, 3, [66] [67] [68] Comparative trials are needed before recommending these regimens for use outside of a clinical trial setting.
RECENTLY TESTED AGENTS
Despite the large number of agents screened recently for anticancer activity against SCCHN in early clinical trials, the number of trials with positive results has been small ( Table 2) . Most of the active agents identified fall into a class of agents already known to have activity against SCCHN. Examples of new agents (and their respective singleagent response rates) in the same class as historically active agents in SCCHN include ifosfamide (26%), pemetrexed (26%), oxaliplatin (10%), capecitabine (8%) and vinorelbine (6%). Active agents with relatively novel mechanisms of action or targets include irinotecan (14%), cetuximab (13%), gefitinib (11%), and erlotinib (4%). [69] [70] [71] [72] [73] [74] [75] [76] In general, the EGFR interactive agents have low single-agent activity in SCCHN, which is surprising given the high rate of EGFR overexpression in SCCHN and prominent activity in preclinical models. 77, 78 Preliminary data from combination trials of EGFR interactive agents with conventional chemotherapy are not encouraging. [79] [80] [81] [82] [83] In phase II studies of refractory patients, response rates and survival are similar to what one would expect from the conventional chemotherapy or EGFR-targeted agents alone. An RCT of CDDP with or without cetuximab demonstrated no significant difference in PFS or OS, but a significantly higher response rate (26% v 10%). Additional toxicity with this combination consisted mainly of rash (Table 3) . 84 Agents presently in clinical trials for which there are little to no data available include investigational agents targeting the microtubule Abbreviations: XRT, radiotherapy; CR, complete response; IV, intravenous infusion; TIP, paclitaxel ϩ ifosfamide ϩ cisplatin; TIC, paclitaxel ϩ ifosfamide ϩ carboplatin; TPF, docetaxel ϩ cisplatin ϩ fluorouracil; PD, progressive disease.
or mitotic apparatus, such as the epothilones and kinesin spindle protein inhibitors, 85, 86 and multiply targeted tyrosine kinase inhibitors such as lapatinib and sorafenib. 87 There are a plethora of agents targeting the vascular endothelial growth factor receptor and its ligand, both small molecules and monoclonal antibodies, presently in clinical trials. A major challenge to the development of these agents is the assumption that they will generate very little single-agent anticancer activity in the clinic, but may be useful in combination with conventional or other targeted therapies, as was the case for bevacizumab in colorectal, lung and breast cancers.
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DISCUSSION AND TREATMENT GUIDELINES
During the last three decades, dozens of new agents have been tested on thousands of patients with metastatic or recurrent SCCHN. MTX, CDDP, CARBO, paclitaxel, docetaxel, and FU have demonstrated significant anti-SCCHN effect in many studies and alone or in combination are the mainstay of anticancer treatment for these patients today.
Unfortunately, it is unclear to what extent the use of these agents has brought about meaningful improvement in clinically relevant outcomes in this setting. No one agent or regimen is known to significantly increase survival compared to other agents. CDDP has been associated with increased survival versus supportive care in only one small study.
21
The clinical benefit of tumor reduction in this setting has never been rigorously studied. However, for every case in which combination treatment containing CDDP has been associated with an improvement in response rate, the proportion of high-grade toxicity is greater as well (Table 3) .
What can be recommended to the physician faced with such patients? Because there are no data on whether early or deferred treatment is preferred, timing of treatment should include consideration of present or risk of future symptoms based on the extent of tumor involvement of a vital organ or structure. The documentation of recurrent disease or presence of metastases should not in itself prompt a decision to begin treatment. Individualized decisions by the physician and patient in these circumstances should focus on benefits of palliation versus the risks of treatment toxicity. Once treatment is initiated, patients should be evaluated relatively early, within two cycles, for response and benefit. In the absence of early evidence of palliation of symptoms or tumor reduction, change or discontinuation of treatment should be considered. One caveat to this recommendation is that cytostatic agents now in clinical trials might require a different time course for evaluation of benefit. Duration of treatment decisions for patients who experience response or palliation are difficult because some toxicities are cumulative and irreversible (eg, neuropathy). Generally patients should be treated until response stabilizes in CR or partial response plus an additional two cycles, but patients for whom palliation is evident and who have minimal adverse effects may be considered for extended treatment. Patients whose tumors do not respond to the first treatment choice are less likely to respond to alternate regimens, but patients with good performance status and significant need of palliation should not a priori be denied additional antineoplastic treatment.
We can make some observations concerning how to administer agents in this population. In the case of MTX, more is not better, and 40 to 60 mg/m 2 intravenously weekly continues to be an appropriate initial treatment for most patients.
17 For paclitaxel, a 1-hour weekly infusion is preferred to a 3-hour or longer infusion on an every-21-days schedule. In the case of docetaxel, the largest experience is with the every every-21-days regimen. CDDP may be preferred to CARBO in the curative treatment setting, but it is unclear whether there is an advantage in the palliation of recurrent disease. CARBO is associated with less nausea, vomiting, and kidney dysfunction.
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Although both the taxanes and platinums are associated with high single-agent response rates, they are certainly more difficult to administer and more costly. Taxanes may be the treatment of choice for patients whose renal dysfunction precludes the use of MTX or CDDP. There are no data that persuasively make the case for the superiority of docetaxel or paclitaxel.
If response is paramount in the decision to treat a patient, then the combination of CDDP ϩ FU or CDDP plus a taxane, despite the increased toxicity versus other treatments, may be the best choice. Some data suggest that the substitution of CARBO for CDDP diminishes response rates.
33 Therefore physicians and patients should be aware that better tolerability may compromise activity in this case. Table 5 lists some regimens in wide clinical use.
Physicians and patients should consider enrollment of patients onto clinical trials. Investigators should challenge themselves to consider settings in which supportive care arms would be acceptable controls, because poor enrollment has crippled trials with supportive care arms in the recent past (A. de Graeff, personal communication, February 2006) . PFS and OS have been virtually unaltered in phase III trials of agents selected on the basis of response rates seen in screening phase II trials. Therefore, investigators should consider the possibility of different screening designs using more clinically relevant end points such as PFS, symptom control, or quality-of-life assessment earlier in a drug's development. Such designs would require greater numbers of patients per trial than is the standard today. Oncologists and patients should be reminded that without a significant increase in the number of patients willing to participate in clinical trials, progress will continue to be slow, for it is difficult to demonstrate incremental gains on the order of 10% to 15% with trials sized as they are today. 24. Chauvergne J, Cappelaere P, Fargeot P, et al: A randomized study comparing cisplatin alone or combined in the palliative treatment of carcinoma of the head and neck: Analysis of a series of 209 patients. Bull Cancer 75:9-22, 1988 25. Clavel M, Cognetti F, Dodion P, et al: Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer 60: [1173] [1174] [1175] [1176] [1177] 1987 26. Vogl SE, Schoenfeld DA, Kaplan BH, et al: A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer 56: [432] [433] [434] [435] [436] [437] [438] [439] [440] [441] [442] 1985 27. Williams SD, Velez-Garcia E, Essessee I, et al: Chemotherapy for head and neck cancer: Comparison of cisplatin ϩ vinblastine ϩ bleomycin versus methotrexate. Cancer 57: [18] [19] [20] [21] [22] [23] 1986 28. Browman GP, Cronin L: Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. 
